Observational studyDer Nervenarzt2026
[Sociodemographic and clinical data among GHB patients-an observational study].
Observational study in Der Nervenarzt, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to its anxiolytic and stimulating effects gammahydroxybutyrate (gamma-hydroxybutyric acid, GHB) has gained popularity among drug users. The rate of dangerous intoxications and withdrawal syndromes is very high.
objectiveThis study was conducted to gain knowledge about the sociodemographic background of GHB users and their motives of consumption. Furthermore, we intended to collect data about the clinical course of withdrawal treatment, its risks, and complications.
methodsA group of 34 patients who had been consecutively admitted to our hospital for withdrawal treatment was asked for informed consent. The participants fullfilled a semiquantative questionnaire giving information about their socioeconomic background and their history of addictive disease. We also collected clinical data about the course and complications of the withdrawal treatment in our clinic. All patients received treatment as usual.
resultsMost of the participants were male, well educated, and rather young (mean age 34). Very few had children of their own or lived in a partnership. None of them had a history of criminal activities. There were prior contacts with other drugs, especially amphetamines. During detoxification, the rate of withdrawal delirium was very high (40%).
conclusionIn order to improve our treatment and prevention of GHB addictive disease, we need to learn more about the patient groups who are at risk of becoming addicted to GHB. It is further crucial to develop clinical treatment standards to reduce the high rates of delirium and premature treatment interruption.
Indexed as
Identifiers
40445309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.